1 unchanged sentence
Issuer Purchases of Equity Securities
−Removed: The following table includes information about our common stock repurchases during the three-month period ended December 31, 2020.
−Removed: Period Total Number of Shares Purchased(1) Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly
−Removed: Announced Programs(1) Approximate Dollar Value of Shares that may
−Removed: yet be Purchased Under the Program(1)
−Removed: October 1, 2020 through October 31, 2020 — $ — —
−Removed: November 1, 2020 through November 30, 2020 — $ — —
−Removed: December 1, 2020 through December 31, 2020 6,343,100 $ 78.85 6,343,100
−Removed: Total 6,343,100 $ 78.85 6,343,100 $ 1,897,272,535
On July 25, 2012, we announced that our Board of Directors authorized us to repurchase up to $2.0 billion of our common stock on the open market or in private transactions.
The Board of Directors increased this authority by $1.5 billion in each of November 2016 and February 2018, by an additional $2.0 billion in November 2018 and by an additional $1.5 billion in October 2020.
−Removed: During the fourth quarter of 2020, we repurchased approximately 6.3 million shares for $500 million in cash pursuant to this authority through a Rule 10b5-1 purchase plan.
+Added: During the fourth quarter of 2021, we did not repurchase any shares under this authority.
The remaining authorization under this program totaled approximately $1.3 billion at December 31, 2021.
6 unchanged sentences
The following graph compares the change in our cumulative total stockholder return (including reinvested dividends) on our common stock with the Standard & Poor’s 500 Composite Index and the Standard & Poor’s 500 Health Care Index over the past five years.
−Removed: Selected Financial Data.
−Removed: The following selected consolidated financial data should be read in conjunction with our consolidated financial statements and the accompanying notes thereto in Item 8 of this Annual Report on Form 10-K, and the information contained in Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K.
−Removed: as of or for the years ended December 31 2020 2019¹ 2018 2017 2016²
−Removed: Operating Results Net sales $ 11,673 11,362 11,099 10,584 10,133
−Removed: (in millions) Income from continuing operations $ 1,110 1,011 1,552 609 4,936
−Removed: Loss from discontinued operations, net of tax $ — — (6) (7) (1)
−Removed: Net income attributable to Baxter stockholders $ 1,102 1,001 1,546 602 4,935
−Removed: Earnings per share from continuing operations
−Removed: Basic $ 2.17 1.97 2.91 1.12 9.04
−Removed: Diluted $ 2.13 1.93 2.84 1.10 8.96
−Removed: Loss per share from discontinued
−Removed: Basic $ — — (0.01) (0.01) —
−Removed: Diluted $ — — (0.01) (0.02) —
−Removed: Earnings per share
−Removed: Basic $ 2.17 1.97 2.90 1.11 9.04
−Removed: Diluted $ 2.13 1.93 2.83 1.08 8.96
−Removed: Weighted-average
−Removed: number of shares outstanding
−Removed: Basic 509 509 534 543 546
−Removed: Diluted 517 519 546 555 551
−Removed: Balance Sheet Information Total assets $ 20,019 18,193 15,720 17,102 15,459
−Removed: (in millions) Total liabilities $ 11,293 10,281 7,854 7,993 7,238
−Removed: Total equity $ 8,726 7,912 7,866 9,109 8,221
−Removed: Long-term debt and finance lease obligations $ 5,786 4,809 3,481 3,512 2,774
−Removed: Cash Flow Information Cash flows from operations - continuing operations $ 1,870 2,110 2,017 1,730 1,588
−Removed: (in millions) Cash flows from investing activities - continuing operations $ (1,179) (1,100) (916) (1,292) (716)
−Removed: Cash flows from financing activities $ (345) 498 (2,603) 93 (324)
−Removed: Capital expenditures - continuing operations $ (709) (696) (659) (616) (705)
−Removed: Common Stock Information Cash dividends declared per share $ 0.955 $ 0.850 $ 0.730 $ 0.610 $ 0.505
−Removed: _______________________________________________________________
−Removed: Income from continuing operations for the year ended December 31, 2019 included a pre-tax charge of $755 million ($568 million, or $1.09 per diluted share, on an after-tax basis) related to the annuitization of a portion of our U.S.
−Removed: pension plan.
−Removed: Income from continuing operations for the year ended December 31, 2016 included pre-tax net realized gains of $4.4 billion ($4.4 billion, or $8.07 per diluted share, on an after-tax basis) related to the disposition of our formerly retained shares in Baxalta (Baxalta Retained Shares).
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.